Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00889577

Enrollment

233

Registered

2009-04-29

Start date

2008-12-31

Completion date

2013-12-31

Last updated

2023-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, HIV Infections, Non-Alcoholic Fatty Liver Disease

Brief summary

The primary purpose of this study is to evaluate the association between nonalcoholic fatty liver disease (NAFLD) by computed tomography (CT) scan and coronary artery disease (CAD) measured by the calcium (CAC) score among HIV-infected persons.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* HIV patients who participated in our previous Liver Study, conducted at NMCSD, and HIV patients who did not participate in the Liver Study.

Exclusion criteria

* Women who are pregnant or breastfeeding will be excluded.

Design outcomes

Primary

Measure	Time frame
Coronary artery disease (CAD) measured by the CAC score	1 year

Secondary

Measure	Time frame
To evaluate predictors for coronary artery disease including demographics, concurrent conditions (e.g., diabetes, hyperlipidemia, tobacco use), and HIV factors such as ARV duration, HIV duration, and lipodystrophy	1 year
To investigate the relationship between inflammatory markers (CRP, ESR), d-dimer, adiponectin levels, future inflammatory markers, and genetic polymorphisms with the presence of coronary disease and NAFLD	1 year
To assess the relationship between increased pericardial fat on CT scan with visceral fat and cardiovascular disease	1 year
To determine the prevalence of coronary artery disease as determined by computed tomography (CT) of the coronary arteries among HIV patients, and to compare it to data from the general population using normative data from recent publications	1 year
To measure the pulmonary artery size to evaluate for prevalence of asymptomatic pulmonary hypertension among HIV-infected persons	1 year
To describe the outcome of a positive CAC score in terms of follow-up test/procedure results to help describe the clinical significance of elevated scores.	1 year
To determine if Hounsfield units taken in the heart and aorta estimates hemoglobin levels	1 year

Countries

United States

Outcome results